Antje J. Neeb

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications

Corrigendum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [European Urology 83 (2023) 224-238.

Corrigendum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [European Urology 83 (2023) 224-238.

Journal: European urology
Published: August 07, 2026

Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers.

Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers.

Journal: The Journal of clinical investigation
Published: July 23, 2025

An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer.

An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer.

Journal: European urology oncology
Published: July 14, 2025

Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer.

Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer.

Journal: NPJ precision oncology
Published: June 05, 2025

Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer.

Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer.

Journal: iScience
Published: January 27, 2025

NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth.

NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 29, 2024

Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer.

Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer.

Journal: Nature communications
Published: March 07, 2024

BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity.

BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity.

Journal: The Journal of clinical investigation
Published: February 06, 2024

RNASEH2B loss and PARP inhibition in advanced prostate cancer.

RNASEH2B loss and PARP inhibition in advanced prostate cancer.

Journal: The Journal of clinical investigation
Published: December 08, 2023

BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress.

BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress.

Journal: Nature communications
Published: October 20, 2023

Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer.

Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer.

Journal: Molecular cancer therapeutics
Published: June 08, 2023

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.

Journal: Nature
Published: May 23, 2023
Showing 1-12 of 47

Last Updated: 09/26/2026